{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:27Z","timestamp":1788516447008,"version":"build-2803163510"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.17375","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T15:01:51Z","timestamp":1655218911000},"page":"e2217375","source":"Crossref","is-referenced-by-count":38,"title":["Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries"],"prefix":"10.1001","volume":"5","author":[{"given":"Jacob","family":"Dag Berild","sequence":"first","affiliation":[{"name":"Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilde","family":"Bergstad Larsen","sequence":"additional","affiliation":[{"name":"Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Myrup Thiesson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Lehtonen","sequence":"additional","affiliation":[{"name":"The Information Services Department, Finnish Institute for Health and Welfare, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Gr\u00f8sland","sequence":"additional","affiliation":[{"name":"Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Helgeland","sequence":"additional","affiliation":[{"name":"Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wolhlfahrt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vinsl\u00f8v Hansen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto A.","family":"Palmu","sequence":"additional","affiliation":[{"name":"The Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hviid","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark"},{"name":"Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"issue":"5","key":"zoi220506r1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"zoi220506r2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10269","key":"zoi220506r3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"zoi220506r4","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi220506r5","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi220506r6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/pto.2010.106.issue-2","article-title":"The Nordic countries as a cohort for pharmacoepidemiological research.","volume":"106","author":"Furu","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"17","key":"zoi220506r8","doi-asserted-by":"publisher","first-page":"30520","DOI":"10.2807\/1560-7917.ES.2017.22.17.30520","article-title":"Establishing and maintaining the National Vaccination Register in Finland.","volume":"22","author":"Baum","year":"2017","journal-title":"Euro Surveill"},{"issue":"17","key":"zoi220506r9","doi-asserted-by":"publisher","first-page":"20155","DOI":"10.2807\/ese.17.17.20155-en","article-title":"The Danish vaccination register.","volume":"17","author":"Grove Krause","year":"2012","journal-title":"Euro Surveill"},{"issue":"16","key":"zoi220506r10","doi-asserted-by":"publisher","first-page":"20147","DOI":"10.2807\/ese.17.16.20147-en","article-title":"The Norwegian immunisation register--SYSVAK.","volume":"17","author":"Trogstad","year":"2012","journal-title":"Euro Surveill"},{"issue":"1","key":"zoi220506r11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1403494819859737","article-title":"The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: research potential of two nationwide health-care registries.","volume":"48","author":"Bakken","year":"2020","journal-title":"Scand J Public Health"},{"key":"zoi220506r12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential.","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"6","key":"zoi220506r13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","article-title":"Quality of the Finnish Hospital Discharge Register: a systematic review.","volume":"40","author":"Sund","year":"2012","journal-title":"Scand J Public Health"},{"key":"zoi220506r14","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs.","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"zoi220506r15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/rssb.1995.57.issue-1","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"1","key":"zoi220506r16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/107327481001700108","article-title":"The false discovery rate: a key concept in large-scale genetic studies.","volume":"17","author":"Chen","year":"2010","journal-title":"Cancer Control"},{"issue":"1","key":"zoi220506r17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/pds.v22.1","article-title":"Drug safety studies and measures of effect using the self-controlled case series design.","volume":"22","author":"Wilson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1114","key":"zoi220506r18","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study.","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"zoi220506r19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","volume":"27","author":"Simpson","year":"2021","journal-title":"Nature Medicine"},{"key":"zoi220506r21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2021.06.016","article-title":"Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.","volume":"205","author":"Campello","year":"2021","journal-title":"Thromb Res"},{"issue":"3","key":"zoi220506r23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review.","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"zoi220506r24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1186\/s12913-021-07233-2","article-title":"Utilization of health care services before and after media attention about fatal side effects of the AstraZeneca vaccine: a nation-wide register-based event study.","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"zoi220506r7","unstructured":"Emergency preparedness register for COVID-19 (Beredt C19). Norwegian Institute of Public Health. Accessed September 28, 2021. https:\/\/www.fhi.no\/en\/id\/infectious-diseases\/coronavirus\/emergency-preparedness-register-for-covid-19\/"},{"key":"zoi220506r20","unstructured":"European Medicines Agency. EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome. European Medicines Agency. Accessed September 28, 2021. https:\/\/www.ema.europa.eu\/en\/news\/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia"},{"key":"zoi220506r22","unstructured":"European Medicines Agency. AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. European Medicines Agency. Accessed September 28, 2021. https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2793348\/dag_berild_2022_oi_220506_1654628746.57678.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T15:01:54Z","timestamp":1655218914000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2793348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.17375","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]}}}